

19<sup>th</sup> PRCP 2021, Seoul, Hybrid, 8-10 April 2021 Link

Dear the REAP survey members,

We would like to report the REAP Survey in the PRCP, Seoul, Korea

The 19th International Congress of the Pacific Rim College of Psychiatrists (PRCP) was held for the period of April 8-10, 2021 in Seoul, Korea. Because of the COVID-19 pandemic, the international congress was conducted with a hybrid form of offline and online meeting. Prof. Yong Chon Park, who is the president of the Korean Neuropsychiatric Association (KNPA), successfully organized the 19th international Congress of the PRCP. Under the leadership of Prof. Naotaka Shinfuku, the REAP survey members organized the two symposia as follows:

First, the symposium 14, entitled as “why psychiatrists tend to make a polypharmacy decision-making in daily clinical practice?”, was moderated by Prof. Naotaka Shinfuku (Japan) and Prof. Takahiro A. Kato (Japan). The symposium contents consist of (i) overview of polypharmacy in Asian countries based on REAP survey (Prof. Chay Hoon Tan, Singapore), (ii) network-based analyses of patterns of psychotropic medication uses in Asian patients with schizophrenia (Prof. Seon-Cheol Park, Korea), (iii) how to face and combat polypharmacy-based clinical practice: case reports from an early-career psychiatrist (Prof. Muneomi Kayo, Japan), and (iv) a call for a rational polypharmacy: based on an international survey on psychiatrists’ decision-making (Prof. Yukako Nakagami, Japan). Prof. Norman Sartorius (Switzerland) discussed the symposium 14 contents (see fig; see abstract book p. 24-25).

Second, the symposium 19, entitled as “side effects of psychotropic agents in Asia”, was moderated by Prof. Toshiya Inada (Japan) and Prof. Seon-Cheol Park (Korea). The symposium contents consist of (i) the factor structure of EPS using the DIEPSS in patients with schizophrenia: results from 2016 REAP AP-4 study (Prof. Chika Kubota, Japan), (ii) profile antipsychotics among schizophrenia patient in Indonesia: results from the Research on Asia Psychotropic Prescription (REPA) studies (Prof. Andi Jayalangkara Tanra, Indonesia), (iii) brief introduction on prescription pattern and clinical characteristics of patients with mood stabilizer-induced cognitive side effects: findings from the REAP-BD survey in Korea (Prof. Kiwon Kim, Korea), (iv) adverse events related to antipsychotic medications in Asia: trend analysis from REAP-AP 1-4 (Prof. Kok Yoon Chee, Malaysia), and (v) REAP-AP survey: what does data from India suggest? (Prof. Sandeep Grover, India). Prof. Chay Hoon Tan (Singapore) discussed the symposium 19 contents (see abstract book p. 31- 33).

We greatly appreciate your collaborating spirit for the PRCP, Seoul, Korea.

Deeply hope you’re safe in a hard time of COVID-19 pandemic.

After overcoming the COVID-19, we are look forward to meeting you.

Best regards,

Yong Chon Park, MD, PhD and Seon-Cheol Park, MD, PhD from Korea.



**Fig.** symposium 14: why psychiatrists tend to make a polypharmacy decision-making in daily clinical practice? in PRCP, Seoul, Korea (April 9 (Fri), 2021)